Putnam Investments’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Putnam Investments’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-44,848	Closed	-$183K	–	1228
2023 Q1	$183K	Buy	44,848 +14,710	+49%	+$68K	﹤0.01%	1124
2022 Q4	$151K	Sell	30,138 -6,762	-18%	-$42.4K	﹤0.01%	1128
2022 Q3	$483K	Sell	36,900 -666	-2%	-$10.1K	﹤0.01%	941
2022 Q2	$482K	Sell	37,566 -446	-1%	-$6.18K	﹤0.01%	948
2022 Q1	$580K	Buy	38,012 +9,920	+35%	+$155K	﹤0.01%	966
2021 Q4	$497K	Buy	+28,092	New	+$539K	﹤0.01%	1024

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Putnam Investments's NGM Position: Q2 2023 in Review

Putnam Investments sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 44,848 shares — an estimated $183K sold.

Putnam Investments first reported a position in NGM in Q4 2021 and held it in 6 quarters. The position peaked at $580K in Q1 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Putnam Investments reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Putnam Investments sold 44,848 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $183K.
Putnam Investments first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Putnam Investments's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $580K in Q1 2022.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Putnam Investments's 13F filing for Q2 2023, filed 14 Aug 2023.